Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108485
Status:
TERMINATED
Last Update Posted:
2016-06-22
First Post:
2005-04-15
Brief Title:
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
Sponsor:
University of Miami
Organization:
University of Miami
Study Overview
Official Title:
Randomized Double-blind Placebo-controlled Trial of Niaspan in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment
Status:
TERMINATED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Unable to recruit sufficient study subjects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan to improve the levels of blood fats good and bad cholesterol and triglyceride levels in people who have kidney damage due to diabetes A secondary goal is to test whether Niaspan slows down further development of kidney damage
Detailed Description:
Diabetic nephropathy is the leading cause of end stage kidney disease in the United States Patients with chronic kidney disease have a markedly increased risk of death from cardiovascular disease and traditional risk factors such as hyperlipidemia have been shown to be of critical importance Almost 90 of patients with diabetes and chronic kidney disease have lipid abnormalities Here we investigate whether Niaspan taken in addition to lipid-lowering drugs referred to as statins will decrease LDL cholesterol and increase LDL particle size increase HDL reduce proteinuria and reduce the speed of loss of renal function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None